These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 14603049)

  • 21. Reflux-associated laryngitis and laryngopharyngeal reflux: a gastroenterologist's point of view.
    Hammer HF
    Dig Dis; 2009; 27(1):14-7. PubMed ID: 19439955
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Specific labelling of gastric H+,K+-ATPase by omeprazole.
    Fryklund J; Gedda K; Wallmark B
    Biochem Pharmacol; 1988 Jul; 37(13):2543-9. PubMed ID: 2839196
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Evaluation and management of laryngopharyngeal reflux.
    Ford CN
    JAMA; 2005 Sep; 294(12):1534-40. PubMed ID: 16189367
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Consequences of long-term proton pump blockade: insights from studies of patients with gastrinomas.
    Jensen RT
    Basic Clin Pharmacol Toxicol; 2006 Jan; 98(1):4-19. PubMed ID: 16433886
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The parietal cell autoantigens recognized in neonatal thymectomy-induced murine gastritis are the alpha and beta subunits of the gastric proton pump [corrected].
    Jones CM; Callaghan JM; Gleeson PA; Mori Y; Masuda T; Toh BH
    Gastroenterology; 1991 Aug; 101(2):287-94. PubMed ID: 1648525
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacological profile of novel acid pump antagonist 7-(4-fluorobenzyloxy)-2,3-dimethyl-1-{[(1S,2S)-2-methyl cyclopropyl]methyl}-1H-pyrrolo[2,3-d]pyridazine (CS-526).
    Ito K; Kinoshita K; Tomizawa A; Inaba F; Morikawa-Inomata Y; Makino M; Tabata K; Shibakawa N
    J Pharmacol Exp Ther; 2007 Oct; 323(1):308-17. PubMed ID: 17630360
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Interaction of anti-ulcer drugs with the gastric proton pump.
    Saccomani G; Hersey SJ
    Drug Metabol Drug Interact; 1989; 7(2-3):161-89. PubMed ID: 2560952
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Discovery and development of the proton pump inhibitor].
    Igata H; Okabe S
    Nihon Rinsho; 1992 Jan; 50(1):11-7. PubMed ID: 1311779
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Trends in laryngopharyngeal reflux: a British ENT survey.
    Karkos PD; Benton J; Leong SC; Karkanevatos A; Badran K; Srinivasan VR; Temple RH; Issing WJ
    Eur Arch Otorhinolaryngol; 2007 May; 264(5):513-7. PubMed ID: 17404773
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Enzyme structure and specific gene expression of gastric proton pump].
    Maeda M
    Yakugaku Zasshi; 1995 Jan; 115(1):15-23. PubMed ID: 7699578
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Specific proton pump inhibitors E3810 and lansoprazole affect the recovery process of gastric secretion in rats differently.
    Tomiyama Y; Morii M; Takeguchi N
    Biochem Pharmacol; 1994 Nov; 48(11):2049-55. PubMed ID: 7802694
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Potassium depletion increases proton pump (H(+)-ATPase) activity in intercalated cells of cortical collecting duct.
    Silver RB; Breton S; Brown D
    Am J Physiol Renal Physiol; 2000 Jul; 279(1):F195-202. PubMed ID: 10894802
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Molecular and cellular regulation of the gastric proton pump.
    Asano S; Morii M; Takeguchi N
    Biol Pharm Bull; 2004 Jan; 27(1):1-12. PubMed ID: 14743830
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Laryngopharyngeal reflux disease with nocturnal gastric acid breakthrough while on proton pump inhibitor therapy.
    Sato K
    Eur Arch Otorhinolaryngol; 2006 Dec; 263(12):1121-6. PubMed ID: 16845517
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Characterisation of proton pump antibodies and stomach pathology in gastritis induced by neonatal immunisation without adjuvant.
    Greenwood DL; Sentry JW; Toh BH
    Autoimmunity; 2001; 34(2):81-94. PubMed ID: 11905846
    [TBL] [Abstract][Full Text] [Related]  

  • 36. ME-3407, a new antiulcer agent, inhibits acid secretion by interfering with redistribution of H(+)-K(+)-ATPase.
    Urushidani T; Muto Y; Nagao T; Yao X; Forte JG
    Am J Physiol; 1997 May; 272(5 Pt 1):G1122-34. PubMed ID: 9176222
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect of pepsin on laryngeal stress protein (Sep70, Sep53, and Hsp70) response: role in laryngopharyngeal reflux disease.
    Johnston N; Dettmar PW; Lively MO; Postma GN; Belafsky PC; Birchall M; Koufman JA
    Ann Otol Rhinol Laryngol; 2006 Jan; 115(1):47-58. PubMed ID: 16466100
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Control of gastric acid secretion in health and disease.
    Schubert ML; Peura DA
    Gastroenterology; 2008 Jun; 134(7):1842-60. PubMed ID: 18474247
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Expression of claudin-3 in the esophagus and larynx of rat reflux model.
    Xu XB; Hu Y; Wang Y; Lai CJ; Zhang TY
    Auris Nasus Larynx; 2014 Dec; 41(6):539-42. PubMed ID: 24928064
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Laryngeal disorders in patients with gastroesophageal reflux disease.
    Farrokhi F; Vaezi MF
    Minerva Gastroenterol Dietol; 2007 Jun; 53(2):181-7. PubMed ID: 17557046
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.